Indegene Limited recently hosted its 7th annual Digital Summit 2025 in Philadelphia, bringing together senior life sciences executives to explore the transformative power of AI in commercialization. The event, held at the iconic Barnes Foundation, centered around the theme 'From Chaos to Clarity - and Better Decisions' with a strong focus on Generative AI applications in the life sciences industry.

AI Transformation Takes Center Stage

The invite-only summit featured in-depth discussions on various aspects of AI-driven transformation in the life sciences sector. Key topics included:

• Data unification across the value chain
• Agent-augmented workforce
• Generative AI in commercial operations
• Evolving pharmaceutical regulations
• Zero-rep commercial models
• The future of customer engagement

Industry leaders shared real-world insights and showcased programs that have delivered measurable impact, moving beyond the hype of Generative AI to focus on tangible value creation.

The Vital Awards: Recognizing Industry Innovators

A highlight of the summit was the presentation of the Vital Awards, which recognized industry leaders across four categories:

1. Patient Impact
2. Community Impact
3. Organizational Impact
4. Market Impact

The awards celebrated life sciences professionals at the forefront of scientific and technological convergence, honoring those who embody bold thinking, transformative work, and an unwavering pursuit of progress in healthcare.

Award Recipients and Jury

The Vital Awards 2025 honored several distinguished professionals:

• Patient Impact: Sunil Verma, SVP, Global Head, Oncology Franchise, AstraZeneca
• Organizational Impact:
  • Nathan Bowmaker, Head of Global Commercial Operations, AstraZeneca
  • Catherine Galvin, VP, Global Marketing Digital & AI Business Transformation, Merck
• Market Impact: Marion Dumas, Global Head of Omnichannel, Sanofi

The awards were judged by a distinguished cross-disciplinary jury, including senior leaders from companies such as Gilead Sciences, Merck, and academic institutions like Rutgers University.

Indegene's Commitment to Future-Ready Healthcare

Manish Gupta, Chairman and CEO of Indegene, congratulated the honorees, stating, "Your innovation and impact are helping our industry shift growth trajectories and become future-ready, inspiring the broader ecosystem to redefine what's possible."

The Digital Summit 2025 is part of Indegene's #FutureReadyHealthcare initiative, which aims to facilitate open exchange of ideas, encourage collaboration, and promote thought leadership in the life sciences industry.

As a tech-native, life sciences specialist, Indegene continues to play a crucial role in orchestrating the path from commercialization strategy to execution, helping life sciences leaders move at the speed of their ambition with practitioner-level confidence.

For those interested in learning more about the insights shared at the summit, session recordings and summaries are available at https://digitalsummit.indegene.com/ .

Indegene Limited, a digital-first life sciences commercialization company, has announced a strategic partnership with Datavant, a leading healthcare data collaboration platform. This collaboration aims to significantly enhance patient recruitment for clinical trials, with a particular focus on rare diseases and complex studies.

Streamlining Patient Recruitment

The partnership integrates Datavant's data enrichment capabilities into Indegene's NEXT Patient Recruitment platform. This integration is set to address one of the most significant challenges in clinical development: efficient patient recruitment, especially for rare diseases where eligible populations are often small and geographically dispersed.

Leveraging Big Data

Datavant's impressive network spans over 80,000 hospitals and clinics, processing more than 100 million patient records annually. This vast data resource, combined with Indegene's digital-first approach to clinical trial recruitment, promises to streamline the identification of suitable participants based on specific health data criteria.

Benefits for Patients and Pharmaceutical Companies

The collaboration is expected to yield multiple benefits:

1. Faster trial enrollment
2. Reduced screen failures
3. Improved screen-to-randomization ratios
4. Accelerated enrollment timelines

For patients, particularly those with rare and complex diseases, this partnership means increased opportunities to connect with trials designed for their specific health conditions.

Industry Perspectives

Arnaub Chatterjee, President and GM of Life Sciences at Datavant, emphasized the partnership's potential impact on rare disease research: "Together with Indegene, we are demonstrating how data enrichment solves that challenge today – and lays the foundation for a new model of clinical research in which sponsors can accelerate recruitment across even the most complex and hard-to-reach populations."

Ram Yeleswarapu, SVP of Enterprise Clinical Solutions at Indegene, highlighted the strategic importance of the partnership: "By integrating secure, real-time access to consented patient medical records into our screening process, we are minimizing one of the greatest challenges in clinical trials – screen failures at sites due to incomplete and ineffective pre-screening."

A Digital-First Approach

This collaboration reinforces Indegene's position as a premier digital-first recruitment partner in the life sciences industry. By leveraging data-driven approaches, the company aims to empower sponsors and sites with solutions that deliver measurable outcomes in clinical trial recruitment and execution.

As the healthcare industry continues to evolve, partnerships like this between Indegene and Datavant demonstrate the growing importance of data-driven solutions in advancing medical research and improving patient outcomes.